|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance 显示文摘 | O'Hare T Shakespeare WC Zhu X | 2009 | Cancer Cell2009，16，5： | 1 |
| 2 | Prospective phase Ⅱ trial of concomitant boost radiotherapy for stage Ⅱ nasopharyngeal carcinoma: an evaluation of response and toxicity显示文摘 | Lu J J Shakespeare T P Thiagarajan A | 2005 | Laryngoscope2005，115，5： | 1 |
| 3 | Disahility and the training of health professionals显示文摘 | Shakespeare T Iezzoni LI Groce NE | 2009 | Lancet2009，374，9704： | 1 |
| 4 | AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation- based resistance显示文摘 | O'HARE T SHAKESPEARE WC ZHU X | 2009 | Cancer Cell2009，16，5： | 1 |
| 5 | AP24534, a pan-BCR- ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance 显示文摘 | O' Hare T Shakespeare W C Zhu X | 2009 | Cancer Cell2009，16，5： | 1 |
| 6 | Cultural representation of disabled people ;dustbins for disavowal显示文摘 | Shakespeare T | 1994 | Disability and Society1994，9，3： | 1 |
| 7 | AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation- based resistance显示文摘 | O'Hare T Shakespeare WC Zhu X | 2009 | Cancer Cell2009，16，40： | 1 |
| 8 | AP24534, a pan-BCR-ABL inhibitor for chronic mye- loid leukemia,potently inhibits the T315I mutant and overcomes mutation-based resistance 显示文摘 | O'HARE T SHAKESPEARE W C ZHU X | 2009 | Cancer Cell2009，16，5： | 1 |
| 9 | AP24534,a pan-BCR-ABL inhibitor for chronic myeloid leukemia,potently inhibits the T315I mutant and overcomes muta- tion-based resistance显示文摘 | O' Hare T Shakespeare WC Zhu X | 2009 | Cancer Cell2009，16，5： | 1 |
| 10 | A Fluorescent extension to the Kubelka-Munk model显示文摘 | SHAKESPEARE T SHAKESPEAR J E | 2003 | Color Research & Application2003，28，1： | 1 |
| 11 | International Clinical Recommendations on Scar Management显示文摘 | Thomas A. Mustoe Rodney D. Cooter Michael H. Gold F. D. Richard Hobbs Albert-Adrien Ramelet Peter G. Shakespeare Maurizio Stella Luc Téot Fiona M. Wood Ulrich E. Ziegler | 2002 | Plastic and Reconstructive Surgery2002，，2： | 1 |
| 12 | Prevention of spinal cord injury显示文摘 | Von Groote PM Shakespeare T Officer A | 2014 | Inj Prev2014，20，1： | 1 |
| 13 | Bone-Targeted Src kinase inhibitors: novel phyrrdo and pyrazolo-pyrimidine analogues显示文摘 | Sundaramoothi R Shakespear W C Keenan T P | 2003 | Bioorg Med Chem Lett2003，13，： | 1 |
| 14 | Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in T1 and T2 nasopharyngeal carcinoma 显示文摘 | Lu J J Shakespeare T P Tan L K | 2004 | Head Neck2004，26，5： | 1 |
| 15 | AP24534,a PanBCR-ABL inhibitor for chronic myeloid leukemia,potently inhibits the T315I mutant and overcomes mutation-based resistance显示文摘 | O'Hare T Shakespeare WC Zhu X | | 0，，05： | 1 |
| 16 | AP24534,a panBCR-ABL inhibitor for chronic myeloid leukemia,potently inhibits the T315I mutant and overcomes mutation-based resistance显示文摘 | O'Hare T Shakespeare WC Zhu X | 2009 | Cancer Cell2009，16，： | 1 |
| 17 | World report on disability显示文摘 | Shakespeare T Officer A | 2011 | Disabil Rehabil2011，33，1718： | 1 |
| 18 | AP24534, a Pan-BCR-ABL inhibitor for chronic mye- loid leukemia,potently inhibits the T315I mutant and overcomes mutation-based resistance 显示文摘 | O'HARE T SHAKESPEARE W C EIDE C A | 2009 | Cancer Cell2009，16，5： | 1 |
| 19 | AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T3151 mutant and overcomes mutation-based resistance显示文摘 | O'HARE T SHAKESPEARE W C ZHU X | 2009 | Cancer Cell2009，16，5： | 1 |
| 20 | Problems in colour measurement of fluorescent paper grades显示文摘 | Shakespeare T Shakespeare J | 1999 | Analytica Chimica Acta1999，380，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员